Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl- containing thiazolidinediones

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2569-2581

  Lohray, B B ^a,b   Bhushan, Vidya ^b   Reddy, A Sekar ^b   Rao, P Bheema ^b   Reddy, N Jaipal ^b   Harikishore, P ^b   Haritha, N ^b   Vikramadityan, Reeba K ^b   Chakrabarti, Ranjan ^b   Rajagopalan, R ^b   Katneni, K ^b  

^a ZYDUS RESEARCH CENTRE   (India)

^b DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [4 [[1 (PYRIDINE 2 YL) PYRROLIDIN 2 YL]METHOXY] PHENYLMETHYLENE]THIAZOLIDINE 2,4 DIONE MALEATE; ANTILIPEMIC AGENT; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; OBESITY;

ANIMALS; ANTILIPEMIC AGENTS; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PYRIDINES; QUINOLINES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033566136     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980622j     Document Type: Article

References (34)

1. (a) DeFronzo, R. A. The triumvirate: β cell, muscle, liver a collusion responsible for NIDDM. Diabetes 1988, 37, 667.
2. (b) Turner, R. C.; Mathews, D. R.; Clark, A.; O'Rahilly, S.; Rudenski, A. S.; Levy, J. Clin. Endrocrinol Metab. 1988, 2, 327.
3. (c) Reaven, G. M. Diabetes 1988, 37, 1595-1607.
4. (a) Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawanatsu, Y. Studies on Antidiabetic agents. II Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its derivatives. Chem. Pharm. Bull. 1982, 30, 3563-3573 and 3580-3600.
5. (b) Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents X synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
6. (c) Meguro, K.; Fujita, T. EP 0155845, 1985; Chem. Abstr. 1986, 104, 186401a.
7. (d) Sugiyama, Y.; Taketomi, S.; Shimara, Y.; Ikeda, H.; Fujita, T. Effects of Pioglitazone on Glucose and Lipid metabolism in Wistar fatty rats. Arzneim. Forsch. Drug Res. 1990, 40, 263-267.
8. (e) Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and Analogous. 1. Hypolipidemic Agents with Ability to Inhibit Lipid Peroxidation. J. Med. Chem. 1989, 32, 421-428.
9. (f) Yoshioka, T.; Kotazata, E.; Yamazaki, M.; Hasegawa, K. Thiazolidinedione Derivatives, Their preparation and Compositions Containing Them. EP 0139421, 1984; Chem. Abstr. 1985, 103, 540685.
10. (g) Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, E. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N. Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones and Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
11. (h) Eggler, J. F.; Holland, G. F.; Johnson, M. R.; Volkmann, R. A. Hypoglycaemic Thiazolidinediones. U.S. Patent 4,738,972, 1985; Chem. Abstr. 1987, 107, 39794q.
12. (i) Stevenson, R. W.; Hutson, N. J.; Krapp, M. N.; Volkmann, R. A.; Holland, G. F.; Eggler, J. F.; Clark, D. A.; McPherson, R. K.; Haell, K. L.; Danburg, B. H.; Gibbs, E. M.; Krentler, D. K. Actions of Novel Antidiabetic agents Englitazone in Hyperglycemic Hyperinsulinemic ob/ob mice. Diabetes 1990, 39,1 218-1227.
13. (j) Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The Synthesis of BRL-49653 - A Novel and Potent Antihyperglycemic agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-1184.
14. (a) Scrips 1997, 2282, 21.
15. (b) Scrips 1997, 2292, 20.
16. (c) Matsumoto, K.; Miyake, S.; Yano, M.; Ueki, Y.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749.
17. Scrips 1998, 2357, 22.
18. 2 is a Ligand for the Adipocyte Determination Factor PPARγ Cell 1995, 83, 803-812.
19. (b) Lehman, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) J. Biol. Chem. 1996, 270, 12953-12956.
20. (c) Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehman, J. M. The Structure - Activity Relationship between Peroxisome Proliferator-Activated Receptor γ-Agonism and the Antihyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-668.
21. Mukherjee, R.; Davies, P. J. A.; Crombie, D.-L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nadzan, A. M.; Paterniti, J. R., Jr.; Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X-receptor agonists. Nature 1997, 386, 407.
22. Aicher, T. D.; Balkan, B.; Bell, P. A.; Brand, L. J.; Cheon, S. H.; Deems, R. O.; Fell, J. B.; Fillers, W. S.; Fraser, J. D.; Gao, J.; Knorr, D. C.; Kahle, G. G.; Leone, C. L.; Nadelson, J.; Simpson, R.; Smith, H. C. Substituted Tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and Tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as Hypoglycemic Agents. J. Med. Chem. 1998, 41, 4556-4566.
23. Raginato, M. J.; Bailey, S. T.; Krakow, S. L.; Minami, C.; Ishii, S.; Tanaka, H.; Lazar, M. A. A potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator - Activator Receptor γ - activating properties. J. Biol. Chem. 1998, 273, 32679-32684.
24. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Bajji, A. C.; Reddy, K. V.; Reddy, P. R.; Krishna, T. H.; Rao, I. N.; Jajoo, H. K.; Rao, N. V. S. M.; Chakrabarti, R.; Dileepkumar, T.; Rajagopalan, R. Novel Antidiabetic and Hypolipidemic Agents. 3. Benzofuran-Containing Thiazolidinedione. J. Med. Chem. 1999, 42, 1927-1940.
25. (a) Lohray, B. B.; Bhushan, V.; Bheema Rao, P.; Madhavan, G. R.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Rajagopalan, R. Novel Indole containing Thiazolidinedione Derivatives as Potent Euglycemic and Hypolipidaemic Agents. Bioorg. Med. Chem. Lett. 1997, 7, 785.
26. (b) Lohray, B. B.; Bhushan, V.; Bheema Rao, P.; Madhavan, G. R.; Murali, N.; Narasimha Rao, K.; Anantha Reddy, K.; Rajesh, B. M.; Ganapathy Reddy, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Rajagopalan, R.; Rao, N. V. S.; Mamidi; Jajoo, H. K.; Swaminathan Subramaniam. Novel Euglycemic and Hypolipidaemic Agents. 1. J. Med. Chem. 1998, 41, 1619-1630 and references therein.
27. Anji Reddy, K.; Lohray, B. B.; Bhushan, V.; Sekar Reddy, A.; Hari Kishore, P.; Venugopal Rao, V.; Saibaba, V.; Bajji, A. C.; Rajesh, B. M.; Vivekananda Reddy, K.; Chakrabarti, R.; Rajagopalan, R. Novel Antidiabetic and Hypolipidemic Agents: Part 2: An Antioxidant Moiety as Structural Motif. Bioorg. Med. Chem. Lett. 1998, 8, 999-1002.
28. Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [(ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985.
29. Watt, S. D.; Profitt, J. A.; Corey, E. J. A Reagent for α,β-Reduction of conjugated Nitriles. J. Org. Chem. 1975, 40, 127-128.
30. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on Antidiabetic Agents. 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents. J. Med. Chem. 1992, 35, 2617-2626.
31. Calculation: The percent reduction was calculated according to the formula [1 - (TT/OT)/(TC/OC)] × 100, where TT is test day treated, OT is zero day treated, TC is test day control, and OC is zero day control. Statistics: All results are expressed as mean ± SE. The AUC was calculated according to trapezoidal rule. ANOVA was used for testing for significance between the control and treated groups. AP value of <0.05 is considered significant.
32. (a) Kostyanovsky, R. G.; Gella, I. M.; Markov, V. I.; Somojlova, Z. E. Asymmetrical Nonbridgehead Nitrogen-IV Chiroptical Properties of the Amines, N-chloroamines, and Cyanamides. Tetrahedron 1974, 30, 39-45.
33. (b) Loftus, F. The Synthesis of Some 2-Substituted Morpholines. Synth. Commun. 1980, 10, 59-73.
34. (c) Wawzonek, S.; Wilkinson, T. C. The Cyclization of N-Chloro-4-alkylpiperidines. J. Org. Chem. 1966, 31, 1732-1735.